TAZOCIN POWDER FOR SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

PIPERACILLIN (PIPERACILLIN SODIUM); TAZOBACTAM (TAZOBACTAM SODIUM)

Beschikbaar vanaf:

PFIZER CANADA ULC

ATC-code:

J01CR05

INN (Algemene Internationale Benaming):

PIPERACILLIN AND BETA-LACTAMASE INHIBITOR

Dosering:

4G; 500MG

farmaceutische vorm:

POWDER FOR SOLUTION

Samenstelling:

PIPERACILLIN (PIPERACILLIN SODIUM) 4G; TAZOBACTAM (TAZOBACTAM SODIUM) 500MG

Toedieningsweg:

INTRAVENOUS

Eenheden in pakket:

23.15ML

Prescription-type:

Prescription

Therapeutisch gebied:

EXTENDED-SPECTRUM PENICILLINS

Product samenvatting:

Active ingredient group (AIG) number: 0225919002; AHFS:

Autorisatie-status:

CANCELLED POST MARKET

Autorisatie datum:

2015-04-27

Productkenmerken

_ _
_TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_
_ _
_Page 1 of 43 _
PRODUCT MONOGRAPH
PR
TAZOCIN
®
Piperacillin and Tazobactam powder for injection
2.0g/0.25g, 3g/0.375g, 4.0g/0.5g per vial (as piperacillin sodium and
tazobactam sodium)
Lyophilized Powder for Injection
Antibiotic/ß-lactamase Inhibitor
Pfizer Canada Inc
17,300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
April 8, 2014
Submission Control No: 171562
®
TM Wyeth Holdings Corporation, Pfizer Canada Inc., Licensee
_ _
_TAZOCIN (Piperacillin Sodium/Tazobactam Sodium)_
_ _
_Page 2 of 43 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................12
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................19
ACTION AND CLINICAL PHARMACOLOGY
............................................................20
STORAGE AND STABILITY
..........................................................................................23
SPECIAL HANDLING INSTRUCTIONS
.......................................................................23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................23
PART II: SCIENTIFIC INFORMATION
....